{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:34:35Z","timestamp":1787661275190,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T00:00:00Z","timestamp":1451347200000},"content-version":"am","delay-in-days":423,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education (ORISE)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"FDA Medical Countermeasures Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.antiviral.2014.09.008","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T20:47:32Z","timestamp":1411159652000},"page":"112-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["In vitro anti-influenza A activity of interferon (IFN)-\u03bb1 combined with IFN-\u03b2 or oseltamivir carboxylate"],"prefix":"10.1016","volume":"111","author":[{"given":"Natalia A.","family":"Ilyushina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond P.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.09.008_b0005","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.bbrc.2007.02.019","article-title":"Protection from lethal influenza virus challenge by oral type I interferon","volume":"355","author":"Beilharz","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2014.09.008_b0010","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of amantadine resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause of concern","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.09.008_b0015","doi-asserted-by":"crossref","first-page":"e1003773","DOI":"10.1371\/journal.ppat.1003773","article-title":"Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia","volume":"9","author":"Crotta","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2014.09.008_b0020","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nrd2175","article-title":"Antiviral agents active against influenza A viruses","volume":"5","author":"De Clercq","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2014.09.008_b0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1086\/518936","article-title":"Surveillance of resistance to adamantanes among influenza A (H3N2) and A (H1N1) viruses isolated worldwide","volume":"196","author":"Deyde","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.09.008_b0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.it.2011.07.002","article-title":"Interferon-lambda and therapy for chronic hepatitis C virus infection","volume":"32","author":"Donnelly","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.antiviral.2014.09.008_b0035","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.4049\/jimmunol.164.8.4220","article-title":"Type I IFN modulates innate and specific antiviral immunity","volume":"164","author":"Durbin","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2014.09.008_b0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12101","article-title":"Interferon induction and function at the mucosal surface","volume":"255","author":"Durbin","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.antiviral.2014.09.008_b0045","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1128\/AAC.02239-12","article-title":"Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication","volume":"57","author":"Friborg","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.09.008_b0050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.antiviral.2013.02.013","article-title":"Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002\u20132012 shows need for continued monitoring","volume":"98","author":"Govorkova","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.09.008_b0055","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1128\/AAC.48.12.4855-4863.2004","article-title":"Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells","volume":"48","author":"Govorkova","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.09.008_b0060","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3390\/v2081510","article-title":"Combination chemotherapy for influenza","volume":"2","author":"Govorkova","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2014.09.008_b0065","doi-asserted-by":"crossref","first-page":"202","DOI":"10.7883\/yoken.JJID.2007.202","article-title":"High frequency of amantadine-resistant influenza A (H3N2) viruses in the 2005\u20132006 season and rapid detection of amantadine-resistant influenza A (H3N2) viruses by MAMA-PCR","volume":"60","author":"Hata","year":"2007","journal-title":"Jpn. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.09.008_b0070","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/j.1460-2075.1985.tb04038.x","article-title":"The molecular basis of the specific anti-influenza action of amantadine","volume":"4","author":"Hay","year":"1985","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2014.09.008_b0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0166-3542(95)00914-0","article-title":"Combination antiviral therapy for respiratory virus infections","volume":"29","author":"Hayden","year":"1996","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.09.008_b0080","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1128\/AAC.17.5.865","article-title":"Plaque inhibition assay for drug susceptibility testing of influenza viruses","volume":"17","author":"Hayden","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.09.008_b0085","doi-asserted-by":"crossref","first-page":"e32947","DOI":"10.1371\/journal.pone.0032947","article-title":"Critical role of constitutive type I interferon response in bronchial epithelial cells to influenza infection","volume":"7","author":"Hsu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.09.008_b0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.antiviral.2009.03.003","article-title":"Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa","volume":"83","author":"Hurt","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.09.008_b0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.antiviral.2006.10.004","article-title":"Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes","volume":"73","author":"Hurt","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.09.008_b0100","doi-asserted-by":"crossref","first-page":"e1000043","DOI":"10.1371\/journal.ppat.1000043","article-title":"Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses","volume":"4","author":"Ilyushina","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2014.09.008_b0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.antiviral.2014.09.008_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.13.05.08026-en","article-title":"Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe","volume":"13","author":"Lackenby","year":"2008","journal-title":"Euro. Surveill."},{"key":"10.1016\/j.antiviral.2014.09.008_b0115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.antiviral.2012.09.013","article-title":"Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection","volume":"96","author":"Lee","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.09.008_b0120","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/S0264-410X(03)00075-6","article-title":"The role of antivirals in the control of influenza","volume":"21","author":"Monto","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.09.008_b0125","doi-asserted-by":"crossref","first-page":"e1000151","DOI":"10.1371\/journal.ppat.1000151","article-title":"Interferon-\u03bb contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses","volume":"4","author":"Mordstein","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2014.09.008_b0130","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1128\/JVI.00272-10","article-title":"Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections","volume":"84","author":"Mordstein","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.09.008_b0135","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3949\/ccjm.76a.09047","article-title":"The resurgence of swine-origin influenza A (H1N1)","volume":"76","author":"Mossad","year":"2009","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.antiviral.2014.09.008_b0140","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hep.23743","article-title":"Phase 1b study of pegylated interferon-lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection","volume":"52","author":"Muir","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.antiviral.2014.09.008_b0145","doi-asserted-by":"crossref","first-page":"e310006","DOI":"10.1371\/journal.pone.0031006","article-title":"Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses","volume":"7","author":"Nguyen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.09.008_b0150","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0140-6736(03)14854-4","article-title":"Influenza","volume":"362","author":"Nicholson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.09.008_b0155","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1128\/JVI.01619-09","article-title":"Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons","volume":"84","author":"Osterlund","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.09.008_b0160","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1128\/JVI.01050-12","article-title":"Incoming influenza A virus evades early host recognition, while influenza B virus induces interferon expression directly upon entry","volume":"86","author":"Osterlund","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.09.008_b0165","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0092-8674(92)90452-I","article-title":"Influenza virus M2 protein has ion channel activity","volume":"69","author":"Pinto","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2014.09.008_b0170","series-title":"MacSynergy\u2122 II","author":"Prichard","year":"1992"},{"key":"10.1016\/j.antiviral.2014.09.008_b0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug\u2013drug combinations","volume":"14","author":"Prichard","year":"1990","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.09.008_b0180","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1089\/jir.2010.0066","article-title":"Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C","volume":"30","author":"Ramos","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.antiviral.2014.09.008_b0185","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/jir.2010.0125","article-title":"Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes","volume":"3","author":"Scagnolari","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.antiviral.2014.09.008_b0190","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.antiviral.2014.09.008_b0195","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2217\/fvl.13.98","article-title":"Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice","volume":"8","author":"Smee","year":"2013","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2014.09.008_b0200","doi-asserted-by":"crossref","first-page":"e1000017","DOI":"10.1371\/journal.ppat.1000017","article-title":"IFN-lambda (IFN-\u03bb) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo","volume":"4","author":"Sommereyns","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2014.09.008_b0205","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1128\/JVI.02144-08","article-title":"Early control of H5N1 of influenza virus replication by the type I interferon in mice","volume":"83","author":"Szretter","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.09.008_b0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2012.03.001","article-title":"Combinations of favipiravir and peramivir for the treatment of pandemic influenza A\/California\/04\/2009 (H1N1) virus infections in mice","volume":"94","author":"Tarbet","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.09.008_b0215","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1128\/JVI.02174-08","article-title":"Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding","volume":"83","author":"van Hoeven","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.09.008_b0220","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/prot.340140302","article-title":"The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor","volume":"14","author":"Varghese","year":"1992","journal-title":"Proteins"},{"key":"10.1016\/j.antiviral.2014.09.008_b0225","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus protection","volume":"363","author":"von Itzstein","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2014.09.008_b0230","unstructured":"World Health Organization. Influenza virus infections in humans. <http:\/\/www.who.int\/influenza\/human_animal_interface\/virology_laboratories_and_vaccines\/influenza_virus_infections_humans_feb14.pdf?ua=1>; 2014 [February 2014]."},{"key":"10.1016\/j.antiviral.2014.09.008_b0235","series-title":"Fields Virology","first-page":"1641","article-title":"Orthomyxoviruses","author":"Wright","year":"2006"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421400271X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421400271X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:26:22Z","timestamp":1759062382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421400271X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":47,"alternative-id":["S016635421400271X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.09.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro anti-influenza A activity of interferon (IFN)-\u03bb1 combined with IFN-\u03b2 or oseltamivir carboxylate","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}